Focus of brain tumour research is shifting towards tumour genesis and genetics, and possible development of individualized treatment plans. Genetic analysis shows recurrent mutation in isocitrate dehydrogenase (IDH1) gene in most Glioblastoma multiforme (GBM) cells. In this review we evaluated the prognostic significance of IDH 1 mutation on the basis of published evidence. Multiple retrospective clinical analyses correlate the presence of IDH1 mutation in GBM with good prognostic outcomes compared to wild-type IDH1. A systematic review reported similar results. Based on the review of current literature IDH1 mutation is an independent factor for longer overall survival (OS) and progression free survival (PFS) in GBM patients when compared to wild-type IDH1. The prognostic significance opens up new avenues for treatment.
JPMA. The Journal of the Pakistan Medical Association
Shamim, M. S.
(2017). Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme. JPMA. The Journal of the Pakistan Medical Association, 67(5), 816-817.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_surg_neurosurg/148
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License